French drugmaker Sanofi secured U.S. antitrust clearance for its $11.6 billion acquisition of Waltham, Mass.-based hemophilia specialist Bioverativ Inc.
The waiting period under the Hart-Scott-Rodino Act related to the deal has expired, which means the transaction has received antitrust clearance.
The acquisition is still subject to other conditions, including the tender of at least a majority of Bioverativ's common stock.
On Feb. 7, Sanofi started a tender offer to buy all of Bioverativ's outstanding shares for $105 apiece in cash. The offer will expire March 7.